Federal Contractor Profile
Access To Advanced Health Institute
$40M obligated·21 awards·1 agencies·7 NAICS
Federal Contracts
Showing award actions 1–34 of 34 funded award actions, most recent first.
- Contracts with positive obligations
- 21
- Funded award actions shown
- 34
- Obligations shown
- $40M
- Awarding agencies
- 1
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of September 16, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Sep 10, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00059 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $113K |
| Sep 10, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023C00018 | 541715 | BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES | $110K |
| Aug 16, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023C00018 | 541715 | BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES | $841K |
| Jul 22, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00059 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $1.9M |
| Jun 26, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023C00018 | 541715 | BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES | $2.8M |
| Mar 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018C00025 | 541714 | IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. | $1.3M |
| Jan 9, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00059 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $780K |
| Aug 28, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00059 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $1.7M |
| Aug 28, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023C00018 | 541715 | BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES | $426K |
| Jul 5, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023C00018 | 541715 | BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES | $810K |
| Aug 23, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018C00025 | 541714 | IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. | $39K |
| Aug 1, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00059 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $3.5M |
| Nov 23, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018C00025 | 541714 | IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. | $3.6M |
| Sep 14, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50121C00087 | 541714 | INFECTIOUS DISEASE RESEARCH INSTITUTE: R&D OF INTRANASAL ADMINISTRATION OF RNA VACCINES AGAINST RESPIRATORY PATHOGENS | $749K |
| Sep 3, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93021P01305 | 325414 | INVESTIGATIONAL PRODUCTS GLA-SE ADJUVANT FORMULATION AND LYOPHILIZED ID93 FROM IDRI FOR DAIDS-FUNDED CLINICAL TRIALS | $781K |
| Jun 9, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00059 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $2.7M |
| Feb 18, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018C00025 | 541714 | IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. | $2.9M |
| Sep 24, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00072 | 541715 | BASE PERIOD, HARMONIZATION AND OPTIMIZATION OF STUDY PROTOCOLS AND ASSAY AND M72 BASE, MANUFACTURING ANDM72 OPTION 1A, MOUSE MODEL YEARS 1 AND 2. | $5.7M |
| Aug 29, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00059 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $3.1M |
| Jul 26, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018C00025 | 541714 | IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. | $753K |
| Jan 29, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019P00265 | 325414 | IDRI VACCINE GRADE ADVUJANTPURCHASE 36 VIALS | $11K |
| Jan 11, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019F00131 | 541714 | IN VITRO ASSESSMENTS OF ANTIMICROBIAL ACTIVITY. | $3K |
| Sep 20, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201000039C | 541711 | TAS::75 0140::TAS | $343K |
| Sep 19, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018C00025 | 541714 | IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. | $2.7M |
| Aug 15, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400041C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $2.3M |
| Jul 10, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018P00918 | 325414 | LS130 AND EM082 LIPOSOMAL ADJUVANTS | $5K |
| Jul 10, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018P00914 | 325414 | LS130 LIPOSOMAL ADJUVANT, 25 UNITS | $6K |
| May 4, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018P00664 | 325414 | IDRI-LS130 LIPOSOMAL ADJUVANT, 42 VIALS | $10K |
| Dec 7, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400041C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $1.4M |
| Mar 22, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400041C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $1.1M |
| Nov 4, 2016 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN27200005 | 541711 | IGF::OT::IGF - 1100009I INFECTIOUS DISEASE RESEARCH INSTITUTE; IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY; TO A27 RDB--3; BIOD CAN 8470038; $638,080; PERIOD OF PERFORMANCE 11/04/2016 TO 10/31/2017 | $638K |
| Nov 3, 2016 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400041C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $1.6M |
| Feb 18, 2016 | Department of Health and Human ServicesNIH, NIAID DEA OA OFC ACQUISITIONS | HHSN272201600340P | 325413 | IGF::OT::IGF FOR OTHER FUNCTIONSINFECTIOUS DISEASE RESEARCH INSTITUTE | $4K |
| Jan 28, 2016 | Department of Health and Human ServicesNIH, NIAID DEA OA OFC ACQUISITIONS | HHSN272201400041C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $1.7M |
Get Alerted Before Access To Advanced Health Institute's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free